MedDataX Logo

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

NCT ID: NCT01045161

Last Updated: 2017-01-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

544 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease. The study will be 56 weeks in duration; a 2-week run-in period followed by a 12-week double-blind, placebo-controlled treatment period. This will be followed by an open-label 40-week treatment period and a 2-week follow up phone call. All patients will receive the higher Aclidinium Bromide during the 40-week open label treatment period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

NCT00891462

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

NCT00970268

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01001494

Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED PHASE3

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00500318

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks

Group Type EXPERIMENTAL

Aclidinium bromide

Intervention Type DRUG

Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.

2

Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks

Group Type EXPERIMENTAL

Aclidinium bromide

Intervention Type DRUG

Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.

3

Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aclidinium bromide

Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.

Intervention Type DRUG

Placebo

Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted
* Current or former cigarette smokers

Exclusion Criteria

* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit
* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1
* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness
* History or presence of asthma verified from medical records
* Chronic use of oxygen therapy greater than or equal to 15 hours per day
* Patient with uncontrolled infection due to HIV and/or active hepatitis
* Patients with a history of hypersensitivity reaction to inhaled anticholinergics
* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Esther Garcia, Ph. D.

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Forest Investigative Site 1493

Birmingham, Alabama, United States

Site Status

Forest Investigative Site 1419

Birmingham, Alabama, United States

Site Status

Forest Investigative Site 1413

Muscle Shoals, Alabama, United States

Site Status

Forest Investigative Site 1353

Pell City, Alabama, United States

Site Status

Forest Investigative Site 1379

Phoenix, Arizona, United States

Site Status

Forest Investigative Site 2065

Fullerton, California, United States

Site Status

Forest Investigative Site 1451

National City, California, United States

Site Status

Forest Investigative Site 1388

Paramount, California, United States

Site Status

Forest Investigative Site 1424

Rolling Hill Estates, California, United States

Site Status

Forest Investigative Site 1427

Sacramento, California, United States

Site Status

Forest Investigative Site 1418

San Diego, California, United States

Site Status

Forest Investigative Site 2009

San Diego, California, United States

Site Status

Forest Investigative Site 1374

Torrance, California, United States

Site Status

Forest Investigative Site 1331

Vista, California, United States

Site Status

Forest Investigative Site 1380

Golden, Colorado, United States

Site Status

Forest Investigative Site 1447

Pueblo, Colorado, United States

Site Status

Forest Investigative Site 1364

Clearwater, Florida, United States

Site Status

Forest Investigative Site 1516

Edgewater, Florida, United States

Site Status

Forest Investigative Site 1403

Hollywood, Florida, United States

Site Status

Forest Investigative Site 1485

Homestead, Florida, United States

Site Status

Forest Investigative Site 1352

Miami, Florida, United States

Site Status

Forest Investigative Site 1391

Naples, Florida, United States

Site Status

Forest Investigative Site 1376

Port Orange, Florida, United States

Site Status

Forest Investigative Site 1372

South Miami, Florida, United States

Site Status

Forest Investigative Site 1407

Trinity, Florida, United States

Site Status

Forest Investigative Site 1185

Winter Park, Florida, United States

Site Status

Forest Investigative Site 1386

Atlanta, Georgia, United States

Site Status

Forest Investigative Site 1411

Calhoun, Georgia, United States

Site Status

Forest Investigative Site 1528

Lawrenceville, Georgia, United States

Site Status

Forest Investigative Site 0679

Coeur d'Alene, Idaho, United States

Site Status

Forest Investigative Site 1385

Elk Grove Village, Illinois, United States

Site Status

Forest Investigative Site 1409

O'Fallon, Illinois, United States

Site Status

Forest Investigative Site 1479

Anderson, Indiana, United States

Site Status

Forest Investigative Site 2022

Evansville, Indiana, United States

Site Status

Forest Investigative Site 1441

Indianapolis, Indiana, United States

Site Status

Forest Investigative Site 1149

South Bend, Indiana, United States

Site Status

Forest Investigative Site 1406

Iowa City, Iowa, United States

Site Status

Forest Investigative Site 1080

Topeka, Kansas, United States

Site Status

Forest Investigative Site 2033

Bowling Green, Kentucky, United States

Site Status

Forest Investigative Site 1090

Hazard, Kentucky, United States

Site Status

Forest Investigative Site 1430

New Orleans, Louisiana, United States

Site Status

Forest Investigative Site 1446

New Orleans, Louisiana, United States

Site Status

Forest Investigative Site 1360

Sunset, Louisiana, United States

Site Status

Forest Investigative Site 1412

Baltimore, Maryland, United States

Site Status

Forest Investigative Site 1518

North East, Maryland, United States

Site Status

Forest Investigative Site 1442

Brockton, Massachusetts, United States

Site Status

Forest Investigative Site 1421

Fall River, Massachusetts, United States

Site Status

Forest Investigative Site 1029

North Dartmouth, Massachusetts, United States

Site Status

Forest Investigative Site 1405

Chelsea, Michigan, United States

Site Status

Forest Investigative Site 0889

Livonia, Michigan, United States

Site Status

Forest Investigative Site 1487

Troy, Michigan, United States

Site Status

Forest Investigative Site 1128

Edina, Minnesota, United States

Site Status

Forest Investigative Site 1527

Fridley, Minnesota, United States

Site Status

Forest Investigative Site 1124

Minneapolis, Minnesota, United States

Site Status

Forest Investigative Site 1118

Rochester, Minnesota, United States

Site Status

Forest Investigative Site 1399

St Louis, Missouri, United States

Site Status

Forest Investigative Site 1400

Missoula, Montana, United States

Site Status

Forest Investigative Site 1354

Bellevue, Nebraska, United States

Site Status

Forest Investigative Site 1367

Bellevue, Nebraska, United States

Site Status

Forest Investigative Site 1476

Fremont, Nebraska, United States

Site Status

Forest Investigative Site 1363

Omaha, Nebraska, United States

Site Status

Forest Investigative Site 1390

Omaha, Nebraska, United States

Site Status

Forest Investigative Site 1422

Omaha, Nebraska, United States

Site Status

Forest Investigative Site 1359

Henderson, Nevada, United States

Site Status

Forest Investigative Site 1355

Las Vegas, Nevada, United States

Site Status

Forest Investigative Site 1486

Albuquerque, New Mexico, United States

Site Status

Forest Investigative Site 1489

Larchmont, New York, United States

Site Status

Forest Investigative Site 1425

New York, New York, United States

Site Status

Forest Investigative Site 1373

North Syracuse, New York, United States

Site Status

Forest Investigative Site 1392

Charlotte, North Carolina, United States

Site Status

Forest Investigative Site 1366

High Point, North Carolina, United States

Site Status

Forest Investigative Site 1136

Cincinnati, Ohio, United States

Site Status

Forest Investigative Site 1371

Cincinnati, Ohio, United States

Site Status

Forest Investigative Site 1361

Columbus, Ohio, United States

Site Status

Forest Investigative Site 1433

Columbus, Ohio, United States

Site Status

Forest Investigative Site 1530

Toledo, Ohio, United States

Site Status

Forest Investigative Site 1393

Zanesville, Ohio, United States

Site Status

Forest Investigative Site 1362

Oklahoma City, Oklahoma, United States

Site Status

Forest Investigative Site 2018

Medford, Oregon, United States

Site Status

Forest Investigative Site 2043

Medford, Oregon, United States

Site Status

Forest Investigative Site 1377

Collegeville, Pennsylvania, United States

Site Status

Forest Investigative Site 1423

Erie, Pennsylvania, United States

Site Status

Forest Investigative Site 1428

Feasterville, Pennsylvania, United States

Site Status

Forest Investigative Site 1443

Philadelphia, Pennsylvania, United States

Site Status

Forest Investigative Site 1510

Pittsburgh, Pennsylvania, United States

Site Status

Forest Investigative Site 1449

Tipton, Pennsylvania, United States

Site Status

Forest Investigative Site 1445

Johnston, Rhode Island, United States

Site Status

Forest Investigative Site 1477

Lincoln, Rhode Island, United States

Site Status

Forest Investigative Site 1144

Columbia, South Carolina, United States

Site Status

Forest Investigative Site 1517

Easley, South Carolina, United States

Site Status

Forest Investigative Site 1506

Grenville, South Carolina, United States

Site Status

Forest Investigative Site 1450

Union, South Carolina, United States

Site Status

Forest Investigative Site 1526

Fayetteville, Tennessee, United States

Site Status

Forest Investigative Site 1356

Knoxville, Tennessee, United States

Site Status

Forest Investigative Site 1417

Knoxville, Tennessee, United States

Site Status

Forest Investigative Site 1389

Amarillo, Texas, United States

Site Status

Forest Investigative Site 1440

Arlington, Texas, United States

Site Status

Forest Investigative Site 1494

Austin, Texas, United States

Site Status

Forest Investigative Site 1375

Houston, Texas, United States

Site Status

Forest Investigative Site 1444

Houston, Texas, United States

Site Status

Forest Investigative Site 1401

Houston, Texas, United States

Site Status

Forest Investigative Site 1381

Houston, Texas, United States

Site Status

Forest Investigative Site 1357

Hurst, Texas, United States

Site Status

Forest Investigative Site 1426

Plano, Texas, United States

Site Status

Forest Investigative Site 1410

Tomball, Texas, United States

Site Status

Forest Investigative Site 1480

Abingdon, Virginia, United States

Site Status

Forest Investigative Site 1402

Lynchburg, Virginia, United States

Site Status

Forest Investigative Site 1404

Norfolk, Virginia, United States

Site Status

Forest Investigative Site 1358

Richmond, Virginia, United States

Site Status

Forest Investigative Site 0988

Tacoma, Washington, United States

Site Status

Forest Investigative Site 1177

Vancouver, British Columbia, Canada

Site Status

Forest Investigative Site 0969

Windsor, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013 Dec;33(12):893-904. doi: 10.1007/s40261-013-0138-1.

Reference Type DERIVED
PMID: 24085591 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4070&filename=las-md-38-synopsis.pdf

las-md-38-synopsis

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LAS-MD-38

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.
NCT01120093 COMPLETED PHASE2
Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00435760 COMPLETED PHASE3
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01437397 COMPLETED PHASE3
Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00868231 COMPLETED PHASE2
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
NCT01966107 COMPLETED PHASE4
Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01471171 COMPLETED PHASE3
Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01462929 COMPLETED PHASE3
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
NCT00358436 COMPLETED PHASE3
BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH
NCT02375724 COMPLETED PHASE4
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT00363896 COMPLETED PHASE3
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01636401 COMPLETED PHASE3
A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02153489 COMPLETED PHASE4
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT01437540 COMPLETED PHASE3
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT01572792 COMPLETED PHASE3
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
NCT01049360 COMPLETED PHASE2
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
NCT03022097 COMPLETED PHASE3
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00706914 TERMINATED PHASE2
Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
NCT01462942 COMPLETED PHASE3
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
NCT01078623 COMPLETED PHASE2
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01908140 COMPLETED PHASE3
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
NCT01425814 COMPLETED PHASE2
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT03276078 COMPLETED PHASE2
Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
NCT02059434 COMPLETED PHASE1
Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD
NCT02109406 COMPLETED PHASE2
The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
NCT00939211 COMPLETED PHASE2